To The Moon

$Terns Pharmaceuticals, Inc.(TERN)$ $Merck(MRK)$  $Viking Therapeutics(VKTX)$  🚀🧬📈 Terns Pharma $TERN Momentum Ignites on Unusual Options Flow and Strategic Takeover Speculation 📈🧬🚀

Terns Pharmaceuticals $TERN is pushing higher again, now +5.4% on the session, and I’m watching this through a very specific lens. This is no longer just a biotech momentum trade, it is becoming a liquidity and positioning event driven by aggressive options flow and a potential strategic re-rating catalyst.

The options tape is where the real signal sits. Over 49K calls have already traded, roughly 89x normal volume, versus just 4.6K puts. That is not retail noise, that is directional conviction. The concentration in the May $15 calls stands out, suggesting positioning for sustained upside rather than a short-lived spike. When call skew stretches this far, it typically precedes either continuation or a volatility event.

What materially changed the narrative is the reported $6.7B acquisition interest linked to Merck. That headline alone explains the +1,486.9% y/y move, but more importantly, it reframes the entire valuation framework. The market is no longer pricing Terns purely on pipeline probability, it is beginning to price strategic optionality. In biotech, that shift can be explosive because it compresses timelines and removes binary risk perception.

Technically, the chart structure is clean and trending with intent. Price has been riding the upper Keltner Channel while consistently holding above the 13 EMA and 21 EMA, both of which are now sloping upward in confirmation. The 55 EMA is acting as a dynamic trend floor, currently sitting well below price, reinforcing the strength of the move.

Bollinger Bands are expanding again after a period of contraction through February, which aligns with the recent breakout into new highs. That volatility expansion phase is typically where trend continuation either accelerates or exhausts.

The key level I am focused on is the breakout zone around $52.80. That level has now been tested intraday after the push to $52.79. A clean hold above this zone turns it into support and opens the path toward a continuation leg higher. If price fails to hold and slips back into the prior channel, I would expect a mean reversion toward the $47–$49 range where prior consolidation and moving average support converge.

Volume confirmation is also critical here. The recent move has been supported by elevated participation, not thin liquidity spikes. That gives the trend more credibility.

From a positioning standpoint, this is where discipline matters. When I see extreme call dominance combined with a headline-driven narrative, I treat it as a high-opportunity but high-risk environment. These setups can extend far beyond what seems rational, but they can also unwind quickly if the catalyst fades or fails to materialise.

What I find most compelling is the alignment across three dimensions: strong technical trend, aggressive options positioning, and a credible strategic catalyst. That combination is rare, and when it appears, it tends to attract both momentum traders and institutional capital simultaneously.

👉❓If the Merck acquisition narrative gains confirmation, do you see $TERN being repriced as a takeover proxy immediately, or does the market demand more pipeline validation before sustaining these levels?

📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀

Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀